Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mepolizumab Effectiveness in Patients With Severe Eosinophilic Asthma and Co-presence of Bronchiectasis
NCT05189613Unknown
- Sponsor
- Azienda Ospedaliero-Universitaria Policlinico G. Rodolico - San Marco
- Start
- Sep 2021
- Primary completion
- Jun 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Trial of mepolizumab in eosinophilic asthma (EA) (2 arms), sponsored by Azienda Ospedaliero-Universitaria Policlinico G. Rodolico - San Marco. Primary endpoint: Asthma Control Test score at 52 weeks. Status: unknown.
02
Drugs
mepolizumab
03
Conditions
eosinophilic asthma (EA)
Beyond the preview
Go deeper on NCT05189613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05189613.